Seth Lederman

CIK: 0001563420

Transaction Breakdown

Open Market Buys (P)4 (36.4%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (36.4%)

Compensation grants

Other (G, F, J, C, D, …)3 (27.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TNXP

Tonix Pharmaceuticals Holding Corp.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

TNXP
Tonix Pharmaceuticals Holding Corp.
Jun 9, 2026
Purchase(P)
Direct
5K shares at avg. $11.79$59K
TNXP
Tonix Pharmaceuticals Holding Corp.
Mar 31, 2026
Purchase(P)
Indirect
5K shares at avg. $12.62$63K
TNXP
Tonix Pharmaceuticals Holding Corp.
Mar 18, 2026
Purchase(P)
Indirect
15K shares at avg. $14.89$223K
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 24, 2026
Award(A)
Stock Option
Direct
134.5K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 24, 2026
Award(A)
Stock Option
Direct
134.5K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
May 15, 2025
Purchase(P)
Direct
4K shares at avg. $21.55$86K
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 25, 2025
Award(A)
Stock Option
Direct
124K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 25, 2025
Award(A)
Stock Option
Direct
124K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 5, 2025
Other(J)
Indirect
0 shares at avg. $3.30$0.726
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 5, 2025
Other(J)
Direct
5 shares at avg. $3.38$17.508
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 5, 2025
Other(J)
Indirect
1 shares at avg. $0.15$0.15

		Type	Shares	Price		Ownership
Jun 9, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Purchase(P)	5,000	$11.79	$58,950	Direct
Mar 31, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Purchase(P)	5,000	$12.62	$63,100	Indirect
Mar 18, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Purchase(P)	15,000	$14.89	$223,350	Indirect
Feb 24, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	134,503	-	-	Direct
Feb 24, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	134,504	-	-	Direct
May 15, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Purchase(P)	4,000	$21.55	$86,200	Direct
Feb 25, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	123,958	-	-	Direct
Feb 25, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	123,958	-	-	Direct
Feb 5, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Other(J)	0	$3.30	$1	Indirect
Feb 5, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Other(J)	5	$3.38	$18	Direct
Feb 5, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Other(J)	1	$0.15	$0	Indirect

1-11 of 11 transactions

About LEDERMAN SETH

LEDERMAN SETH (SEC CIK 0001563420) files insider reports with the SEC as Chief Executive Officer of Tonix Pharmaceuticals Holding Corp. (TNXP).

Signal8 holds 6 ownership filings by LEDERMAN SETH, all Form 4s, filed between Feb 27, 2025 and Jun 9, 2026. Those filings report 11 transactions, from Feb 5, 2025 to Jun 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on LEDERMAN SETH's filings is in BERKELEY HEIGHTS, NJ.

Recent filings by LEDERMAN SETH

Jun 9, 2026: Open-market purchase of TNXP shares (Form 4, code P).
Mar 31, 2026: Open-market purchase of TNXP shares (Form 4, code P).
Mar 18, 2026: Open-market purchase of TNXP shares (Form 4, code P).
Feb 24, 2026: Grants or awards of TNXP derivative securities (2 lines, Form 4, code A).
May 15, 2025: Open-market purchase of TNXP shares (Form 4, code P).

Other insiders filing for Tonix Pharmaceuticals Holding Corp. (TNXP)

Englese Thomas, Chief Commercial Officer
BAGGER RICHARD H, Director
SAENGER BRADLEY, Chief Financial Officer
Taylor Carolyn E., Director
Stillwell Richard Newcomb, Director
OLUKOTUN ADEOYE Y, Director

How to read Form 4 transaction codes